[Homocysteine and rheumatic disease].
In the last decade hyperhomocysteinemia has become an element of great interest as a recognized factor of independent risk for atherotrombosis. Moreover a role has been suggested in some different diseases, like rheumatic ones. Hyperhomocysteinemia could represent a mechanism of amplification of vascular damage in rheumatic disease, therefore it could interact with treatements. Moreover it could contribute to explain the high incidence of cardiovascular events, than they do not find support in traditional risk factors.
Tinazzi
Ilaria
I
Dipartimento di Medicina Clinica e Sperimentale, Università, Verona.
Caramaschi
Paola
P
Patuzzo
Giuseppe
G
Bambara
Lisa Maria
LM
Biasi
Domenico
D
D001172:Arthritis, Rheumatoid / Q000209:etiology; D001528:Behcet Syndrome / Q000209:etiology; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D016022:Case-Control Studies; D004730:Endothelium, Vascular / Q000503:physiopathology; D005260:Female; D006710:Homocysteine / Q000097:blood / Q000378:metabolism; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications* / Q000453:epidemiology / Q000503:physiopathology; D007231:Infant, Newborn; D008297:Male; D015201:Meta-Analysis as Topic; D011446:Prospective Studies; D012216:Rheumatic Diseases / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D012307:Risk Factors; D012595:Scleroderma, Systemic / Q000209:etiology
D006710:Homocysteine